PBS News
1 September 2022 updates as part of the Digital Transformation of Authority Required (Written) PBS listings
From 1 September 2022 the PBS listings for the cancer medicines outlined in the table below will be updated as part of the Department of Health and Aged Care’s digital transformation of Authority Required (Written) Pharmaceutical Benefits Scheme (PBS) listings. Real time assessment of authority requests for these medicines will be available through Services Australia’s Online PBS Authorities (OPA) system, via Health Professional Online Services (HPOS).
For further information on these changes, please refer to the PBS news item published on 30 June 2022, ‘Digital Transformation of Authority Required (Written) PBS listings’.
The Department of Health and Aged Care is working to update all relevant PBS listings as quickly as possible. Further information will be published on the PBS website as groups of medicines are reviewed.
From 1 September 2022 the PBS listings for the following cancer medicines will be updated
| Medicine name, Form, Quantity | PBS item code, Program code | Indication, Treatment phase |
|---|---|---|
| brentuximab vedotin 50 mg injection, 1 vial | 11660Q (IP) | CD30 positive cutaneous T-cell lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 11651F (IB) | CD30 positive cutaneous T-cell lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 10166C (IP) | CD30 positive systemic anaplastic large cell lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 10172J (IN) | CD30 positive systemic anaplastic large cell lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 12646N (IP) | CD30 positive peripheral T-cell lymphoma, non-cutaneous type – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 12656D (IN) | CD30 positive peripheral T-cell lymphoma, non-cutaneous type – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 11089P (IN) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 11073T (IP) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 11080E (IN) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| brentuximab vedotin 50 mg injection, 1 vial | 11079D (IP) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| pembrolizumab 100 mg/4 mL injection, 4 mL vial | 11330H (IP) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| pembrolizumab 100 mg/4 mL injection, 4 mL vial | 11352L (IN) | Relapsed or Refractory Hodgkin lymphoma – Initial treatment |
| crizotinib 200 mg capsule, 60 | 10323H (GE) | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) – Initial treatment |
| crizotinib 200 mg capsule, 60 | 11589Y (GE) | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) – Initial treatment |
| crizotinib 250 mg capsule, 60 | 10322G (GE) | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) – Initial treatment |
| crizotinib 250 mg capsule, 60 | 11594F (GE) | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) – Initial treatment |
| entrectinib 200 mg capsule, 90 | 12092K (GE) | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) – Initial treatment |
| lenalidomide 5 mg capsule, 14 | 12058P (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 5 mg capsule, 14 | 12035K (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 10 mg capsule, 14 | 12004T (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 10 mg capsule, 14 | 12070G (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 15 mg capsule, 14 | 12069F (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 15 mg capsule, 14 | 12012F (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 25 mg capsule, 14 | 12018M (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 25 mg capsule, 14 | 12019N (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle |
| lenalidomide 5 mg capsule, 21 | 12071H (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 5 mg capsule, 21 | 12034J (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 10 mg capsule, 21 | 12060R (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 10 mg capsule, 21 | 12061T (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 15 mg capsule, 21 | 12020P (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 15 mg capsule, 21 | 12026Y (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 25 mg capsule, 21 | 12068E (HS) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 25 mg capsule, 21 | 12059Q (HB) | Multiple Myeloma – Initial treatment (this drug, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle |
| lenalidomide 5 mg capsule, 21 | 11036W (HS) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 5 mg capsule, 21 | 11029L (HB) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 10 mg capsule, 21 | 11063G (HS) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 10 mg capsule, 21 | 11064H (HB) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 15 mg capsule, 21 | 11042E (HS) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 15 mg capsule, 21 | 11062F (HB) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 25 mg capsule, 21 | 11055W (HS) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 25 mg capsule, 21 | 11041D (HB) | Multiple Myeloma – Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation |
| lenalidomide 5 mg capsule, 21 | 9642L (HS) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 5 mg capsule, 21 | 5783J (HB) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 10 mg capsule, 21 | 9643M (HS) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 10 mg capsule, 21 | 5784K (HB) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 15 mg capsule, 21 | 9644N (HS) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 15 mg capsule, 21 | 5785L (HB) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 25 mg capsule, 21 | 9645P (HS) | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 25 mg capsule, 21 | 5786M | Multiple Myeloma – Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease |
| lenalidomide 5 mg capsule, 28 | 11966T (HS) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| lenalidomide 5 mg capsule, 28 | 11967W (HB) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| lenalidomide 10 mg capsule, 28 | 11969Y (HS) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| lenalidomide 10 mg capsule, 28 | 11968X (HB) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| lenalidomide 15 mg capsule, 28 | 11965R (HS) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| lenalidomide 15 mg capsule, 28 | 11964Q (HB) | Multiple Myeloma – Initial treatment with lenalidomide monotherapy in newly diagnosed disease |
| pomalidomide 3 mg capsule, 21 | 10406Q (HB) | Multiple Myeloma – Initial treatment - dual therapy in combination with dexamethasone |
| pomalidomide 3 mg capsule, 21 | 10417G (HS) | Multiple Myeloma – Initial treatment - dual therapy in combination with dexamethasone |
| pomalidomide 4 mg capsule, 21 | 10387Q (HB) | Multiple Myeloma – Initial treatment - dual therapy in combination with dexamethasone |
| pomalidomide 4 mg capsule, 21 | 10386P (HS) | Multiple Myeloma – Initial treatment - dual therapy in combination with dexamethasone |
| pembrolizumab 100 mg/4 mL injection, 4 mL | 12129J (IP) | Relapsed or refractory primary mediastinal B-cell lymphoma – Initial treatment |
| pembrolizumab 100 mg/4 mL injection, 4 mL | 12126F (IN) | Relapsed or refractory primary mediastinal B-cell lymphoma – Initial treatment |
| ruxolitinib 5 mg tablet, 112 | 10614P (GE) |
Intermediate-1 risk myelofibrosis – Initial treatment High risk and intermediate-2 risk myelofibrosis- Initial treatment |
| ruxolitinib 10 mg tablet, 56 | 10913J (GE) |
Intermediate-1 risk myelofibrosis – Initial treatment High risk and intermediate-2 risk myelofibrosis- Initial treatment |
| ruxolitinib 15 mg tablet, 56 | 10619X (GE) |
Intermediate-1 risk myelofibrosis – Initial treatment High risk and intermediate-2 risk myelofibrosis- Initial treatment |
| ruxolitinib 20 mg tablet, 56 | 10618W (GE) |
Intermediate-1 risk myelofibrosis – Initial treatment High risk and intermediate-2 risk myelofibrosis- Initial treatment |
| sonidegib 200 mg capsule, 30 | 11304Y (GE) | Metastatic or locally advanced basal cell carcinoma – Initial treatment and Continuing treatment |
| vismodegib 150 mg capsule, 28 | 11070P (GE) | Metastatic or locally advanced basal cell carcinoma – Initial treatment and Continuing treatment |
| sunitinib 12.5 mg capsule, 28 | 9488J (GE) | Metastatic or unresectable malignant gastrointestinal stromal tumour – Initial treatment |
| sunitinib 25 mg capsule, 28 | 9489K (GE) | Metastatic or unresectable malignant gastrointestinal stromal tumour – Initial treatment |
| sunitinib 37.5 mg capsule, 28 | 10503T (GE) | Metastatic or unresectable malignant gastrointestinal stromal tumour – Initial treatment |
| sunitinib 50 mg capsule, 28 | 9490L (GE) | Metastatic or unresectable malignant gastrointestinal stromal tumour – Initial treatment |
| vorinostat 100 mg capsule, 120 | 11138F (GE) | Cutaneous T-cell lymphoma – Initial treatment |
Last updated
19 August 2022